Exploratory Analysis of
breast cancer
early response
fluorothymidine positron emission tomography scan
neoadjuvant chemotherapy
radiomics
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
08
2020
accepted:
31
05
2021
entrez:
12
7
2021
pubmed:
13
7
2021
medline:
13
7
2021
Statut:
epublish
Résumé
The objective of this study was to evaluate a set of radiomics-based advanced textural features extracted from Patients with operable (T2-T3, N0-N2, M0) or locally advanced (T4, N0-N2, M0) BC were enrolled. All patients underwent chemotherapy (six cycles every 3 weeks). Surgery was performed within 4 weeks of the end of NCT. The MD Anderson Residual Cancer Burden calculator was used to evaluate the pathological response. Twenty patients were included in the study. Lesions from 15 patients were evaluable and analyzed: 9 with pathological complete response (pCR) and 6 with pathological partial response (pPR). Concordance between PET response and histological examination was found in 13/15 patients. LASSO logistic modelling identified a combination of SUV Our study suggests the potential usefulness of FLT-PET for early monitoring of response to NCT. A model based on PET radiomic characteristics could have good discriminatory capacity of early response before the end of treatment.
Identifiants
pubmed: 34249671
doi: 10.3389/fonc.2021.601053
pmc: PMC8264651
doi:
Types de publication
Journal Article
Langues
eng
Pagination
601053Informations de copyright
Copyright © 2021 Fantini, Belli, Azzali, Loi, Bettinelli, Feliciani, Mezzenga, Fedeli, Asioli, Paganelli, Sarnelli and Matteucci.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Eur J Nucl Med Mol Imaging. 2015 May;42(6):818-30
pubmed: 25673053
EJNMMI Phys. 2015 Dec;2(1):26
pubmed: 26501827
Radiology. 2015 Sep;276(3):883-93
pubmed: 25897473
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1461-8
pubmed: 26872788
Clin Cancer Res. 2015 Mar 15;21(6):1258-66
pubmed: 25770293
Methods. 2021 Apr;188:122-132
pubmed: 31978538
Eur Radiol. 2017 Nov;27(11):4498-4509
pubmed: 28567548
Mol Imaging Biol. 2013 Feb;15(1):106-13
pubmed: 22684813
J Clin Oncol. 2012 Sep 10;30(26):3242-9
pubmed: 22649152
Ann Nucl Med. 2016 May;30(4):309-19
pubmed: 26868139
Eur J Cancer. 1999 Dec;35(13):1773-82
pubmed: 10673991
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1515-24
pubmed: 24777490
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
J Clin Oncol. 2012 May 20;30(15):1796-804
pubmed: 22508812
Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8715-21
pubmed: 16361558
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
Mol Imaging Biol. 2006 Jan-Feb;8(1):36-42
pubmed: 16362149
Cancers (Basel). 2019 Aug 31;11(9):
pubmed: 31480470
Ann Surg Oncol. 2012 May;19(5):1508-16
pubmed: 22193884
Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1339-47
pubmed: 17333178
J Clin Oncol. 2005 Apr 20;23(12):2676-85
pubmed: 15837982
J Clin Oncol. 1998 Jan;16(1):93-100
pubmed: 9440728
Med Phys. 2020 Mar;47(3):1167-1173
pubmed: 31830303
Mol Imaging Biol. 2020 Aug;22(4):1070-1077
pubmed: 31758510
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Pattern Recognit. 2009 Jun 1;42(6):1162-1171
pubmed: 20161266
Tomography. 2019 Mar;5(1):161-169
pubmed: 30854454
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Semin Nucl Med. 2007 Nov;37(6):429-39
pubmed: 17920350